{"id":"esaxerenone","rwe":[{"pmid":"41844836","year":"2026","title":"Comment on: Efficacy and safety of esaxerenone vs trichlormethiazide for the treatment of uncontrolled essential hypertension in Japanese patients with type 2 diabetes mellitus: a subanalysis of the EXCITE-HT study.","finding":"","journal":"Hypertension research : official journal of the Japanese Society of Hypertension","studyType":"Clinical Study"},{"pmid":"41629686","year":"2026","title":"Aldosterone-mineralocorticoid receptor interactions: new insights and therapeutic perspectives in primary aldosteronism.","finding":"","journal":"Hypertension research : official journal of the Japanese Society of Hypertension","studyType":"Clinical Study"},{"pmid":"41501370","year":"2026","title":"Positioning esaxerenone, a non-steroidal mineralocorticoid receptor antagonist, in the treatment of hypertension with and without hemodynamic cardiac stress.","finding":"","journal":"Hypertension research : official journal of the Japanese Society of Hypertension","studyType":"Clinical Study"},{"pmid":"41458378","year":"2025","title":"Combined effect of esaxerenone and dapagliflozin on aldosterone-mediated sodium reabsorption and potassium excretion.","finding":"","journal":"Frontiers in physiology","studyType":"Clinical Study"},{"pmid":"41436637","year":"2026","title":"Efficacy and safety of esaxerenone vs trichlormethiazide for the treatment of uncontrolled essential hypertension in Japanese patients with type 2 diabetes mellitus: a subanalysis of the EXCITE-HT study.","finding":"","journal":"Hypertension research : official journal of the Japanese Society of Hypertension","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Mineralocorticoid receptor","category":"target"},{"label":"NR3C2","category":"gene"},{"label":"Active","category":"status"},{"label":"Diabetic nephropathy","category":"indication"},{"label":"Hypertension","category":"indication"},{"label":"Daiichi Sankyo Company, Limited","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Daiichi Sankyo","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=esaxerenone","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:15:23.073161+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Esaxerenone","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:15:30.477743+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:15:28.843895+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=esaxerenone","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:15:29.361042+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Mineralocorticoid receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:15:30.477677+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3545393/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:15:30.058969+00:00"}},"allNames":"minnebro","offLabel":[],"synonyms":["esaxerenone","minnebro","CS-3150","XL-550"],"timeline":[{"date":"2021-08-01","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Daiichi Sankyo Company, Limited)"}],"approvals":[{"date":"2021-08-01","orphan":false,"company":"DAIICHI SANKYO COMPANY, LIMITED","regulator":"PMDA"}],"brandName":"Minnebro","ecosystem":[{"indication":"Diabetic nephropathy","otherDrugs":[],"globalPrevalence":null},{"indication":"Hypertension","otherDrugs":[],"globalPrevalence":1280000000}],"mechanism":{"target":"Mineralocorticoid receptor","targets":[{"gene":"NR3C2","source":"DrugCentral","target":"Mineralocorticoid receptor","protein":"Mineralocorticoid receptor"}],"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Minnebro (esaxerenone) is a selective mineralocorticoid receptor antagonist that competes with aldosterone for binding to the mineralocorticoid receptor, thereby inhibiting the receptor's action and reducing sodium reabsorption in the kidneys."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Esaxerenone","title":"Esaxerenone","extract":"Esaxerenone is a nonsteroidal antimineralocorticoid which was discovered by Exelixis and developed by Daiichi Sankyo Company and is approved in Japan for the treatment of hypertension. It acts as a highly selective silent antagonist of the mineralocorticoid receptor (MR), the receptor for aldosterone, with greater than 1,000-fold selectivity for this receptor over other steroid hormone receptors, and 4-fold and 76-fold higher affinity for the MR relative to the existing antimineralocorticoids spironolactone and eplerenone."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5490","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=esaxerenone","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=esaxerenone","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Esaxerenone","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T11:02:09.926586","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:15:31.755012+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"beclometasone dipropionate","drugSlug":"beclometasone-dipropionate","fdaApproval":"1976-05-12","relationship":"same-target"},{"drugName":"budesonide","drugSlug":"budesonide","fdaApproval":"1994-02-14","patentExpiry":"Sep 9, 2036","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"desoxycorticosterone acetate","drugSlug":"desoxycorticosterone-acetate","fdaApproval":"1939-08-17","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"desoxycorticosterone pivalate","drugSlug":"desoxycorticosterone-pivalate","fdaApproval":"","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"dexamethasone","drugSlug":"dexamethasone","fdaApproval":"1958-10-30","patentExpiry":"Oct 7, 2036","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"dexamethasone phosphate","drugSlug":"dexamethasone-phosphate","fdaApproval":"1959-09-02","relationship":"same-target"},{"drugName":"drospirenone","drugSlug":"drospirenone","fdaApproval":"2019-05-23","patentExpiry":"Jun 28, 2031","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"eplerenone","drugSlug":"eplerenone","fdaApproval":"2002-09-27","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"finerenone","drugSlug":"finerenone","fdaApproval":"2021-07-09","patentExpiry":"Jul 29, 2035","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"fludrocortisone acetate","drugSlug":"fludrocortisone-acetate","fdaApproval":"1955-08-18","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"genericName":"esaxerenone","indications":{"approved":[{"name":"Diabetic nephropathy","source":"DrugCentral","snomedId":127013003,"regulator":"FDA"},{"name":"Hypertension","source":"DrugCentral","snomedId":38341003,"regulator":"FDA","usPrevalence":119900000,"globalPrevalence":1280000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"beclometasone-dipropionate","brandName":"beclometasone dipropionate","genericName":"beclometasone dipropionate","approvalYear":"1976","relationship":"same-target"},{"drugId":"budesonide","brandName":"budesonide","genericName":"budesonide","approvalYear":"1994","relationship":"same-target"},{"drugId":"desoxycorticosterone-acetate","brandName":"desoxycorticosterone acetate","genericName":"desoxycorticosterone acetate","approvalYear":"1939","relationship":"same-target"},{"drugId":"desoxycorticosterone-pivalate","brandName":"desoxycorticosterone pivalate","genericName":"desoxycorticosterone pivalate","approvalYear":"","relationship":"same-target"},{"drugId":"dexamethasone","brandName":"dexamethasone","genericName":"dexamethasone","approvalYear":"1958","relationship":"same-target"},{"drugId":"dexamethasone-phosphate","brandName":"dexamethasone phosphate","genericName":"dexamethasone phosphate","approvalYear":"1959","relationship":"same-target"},{"drugId":"drospirenone","brandName":"drospirenone","genericName":"drospirenone","approvalYear":"2019","relationship":"same-target"},{"drugId":"eplerenone","brandName":"eplerenone","genericName":"eplerenone","approvalYear":"2002","relationship":"same-target"},{"drugId":"finerenone","brandName":"finerenone","genericName":"finerenone","approvalYear":"2021","relationship":"same-target"},{"drugId":"fludrocortisone-acetate","brandName":"fludrocortisone acetate","genericName":"fludrocortisone acetate","approvalYear":"1955","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT02345044","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Subjects","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2015-01","conditions":["Essential Hypertension"],"enrollment":426,"completionDate":"2015-10"},{"nctId":"NCT02448628","phase":"PHASE2","title":"A Phase 2 Exploratory Study of CS-3150 in Japanese Hypertensive Patients With Moderate Renal Impairment","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2015-05","conditions":["Hypertension"],"enrollment":33,"completionDate":"2015-12"},{"nctId":"NCT02722265","phase":"PHASE3","title":"Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2016-03","conditions":["Essential Hypertension"],"enrollment":368,"completionDate":"2017-07-08"},{"nctId":"NCT04019652","phase":"PHASE1","title":"The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2015-11-19","conditions":["Hypertension","Mineralocorticoid Receptor Antagonist"],"enrollment":55,"completionDate":"2015-12-23"},{"nctId":"NCT02848170","phase":"NA","title":"Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2016-08","conditions":["Essential Hypertension"],"enrollment":40,"completionDate":"2017-04"},{"nctId":"NCT02807974","phase":"PHASE3","title":"Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and Albuminuria","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2016-06","conditions":["Hypertension"],"enrollment":51,"completionDate":"2017-03"},{"nctId":"NCT02890173","phase":"PHASE3","title":"Study of CS-3150 in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2016-09","conditions":["Essential Hypertension"],"enrollment":1001,"completionDate":"2017-07-11"},{"nctId":"NCT02808026","phase":"PHASE3","title":"Study of CS-3150 in Patients With Severe Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2016-06","conditions":["Severe Hypertension"],"enrollment":20,"completionDate":"2017-02"},{"nctId":"NCT02885662","phase":"NA","title":"Study of CS-3150 in Patients With Primary Aldosteronism","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2016-09","conditions":["Primary Aldosteronism"],"enrollment":44,"completionDate":"2017-07-20"},{"nctId":"NCT02345057","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Type 2 Diabetic Subjects With Microalbuminuria","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2015-01","conditions":["Diabetic Nephropathy"],"enrollment":365,"completionDate":"2016-07"},{"nctId":"NCT02807987","phase":"PHASE3","title":"Study of CS-3150 in Combination With ARB or ACE Inhibitor in Hypertensive Patients With Moderate Renal Impairment","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2016-06","conditions":["Hypertension With Moderate Renal Impairment"],"enrollment":58,"completionDate":"2017-05-15"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"N62TGJ04A1","INN_ID":"10230","UMLSCUI":"C5139864","chemblId":"CHEMBL3545393","ChEMBL_ID":"CHEMBL3545393","KEGG_DRUG":"D10892","DRUGBANK_ID":"DB15207","PDB_CHEM_ID":" E6R","PUBCHEM_CID":"25052023","IUPHAR_LIGAND_ID":"9894","MESH_SUPPLEMENTAL_RECORD_UI":"C000607547"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Daiichi Sankyo Company, Limited","relationship":"Current Owner"}],"publicationCount":176,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 17","pmid":"41844836","title":"Comment on: Efficacy and safety of esaxerenone vs trichlormethiazide for the treatment of uncontrolled essential hypertension in Japanese patients with type 2 diabetes mellitus: a subanalysis of the EXCITE-HT study.","journal":"Hypertension research : official journal of the Japanese Society of Hypertension"},{"date":"2026 Feb 3","pmid":"41629686","title":"Aldosterone-mineralocorticoid receptor interactions: new insights and therapeutic perspectives in primary aldosteronism.","journal":"Hypertension research : official journal of the Japanese Society of Hypertension"},{"date":"2026 Jan 8","pmid":"41501370","title":"Positioning esaxerenone, a non-steroidal mineralocorticoid receptor antagonist, in the treatment of hypertension with and without hemodynamic cardiac stress.","journal":"Hypertension research : official journal of the Japanese Society of Hypertension"},{"date":"2025","pmid":"41458378","title":"Combined effect of esaxerenone and dapagliflozin on aldosterone-mediated sodium reabsorption and potassium excretion.","journal":"Frontiers in physiology"},{"date":"2026 Feb","pmid":"41436637","title":"Efficacy and safety of esaxerenone vs trichlormethiazide for the treatment of uncontrolled essential hypertension in Japanese patients with type 2 diabetes mellitus: a subanalysis of the EXCITE-HT study.","journal":"Hypertension research : official journal of the Japanese Society of Hypertension"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Daiichi Sankyo","companyId":"daiichi-sankyo","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2021-08-01T00:00:00.000Z","mah":"DAIICHI SANKYO COMPANY, LIMITED","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:15:31.755012+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}